Business

March 21, 2014

Canada approves Biogen Idec's hemophilia treatment

Canada approves Biogen Idec's Alprolix, the first new hemophilia med in 17 years. Alprolix is awaiting US approval and is manufactured in the Triangle, where Biogen employs 1,200 people.

Related content

Comments

Videos

Editor's Choice Videos